Posted in | News | Light / Image Sensor

Visualant Releases ChromaID Scanner for Portable Authentication and Diagnostic Applications

Visualant, Inc., a leading provider of disruptive light-based technologies, announced today the release of its ChromaID™ Scanner to a private team of engineers and scientists, enabling an advanced assessment of new portable identification, authentication and diagnostic applications that are a fraction of the cost and size of current systems used in their respective industries.

Visualant will begin shipping its ChromaID Scanner and Software Development Kit (SDK) to engineers and developers around the globe early this Fall.

“We are eager to introduce a product that not only reduces costs, but also modernizes the current infrastructure of industries that increasingly need to rely on more accurate diagnostics and identification systems,” said Ron Erickson, President and CEO of Visualant. “From laboratory testing, biometric access to identity management and quality control, with our patented ChromaID technology, these processes become as simple as snapping a digital photo, with a portable configuration about the same size of a camera lens embedded into today’s smartphones.”

Recent studies show that disruptive photonic technologies are the innovation catalysts for several multi-billion dollar industries. According to the “Optics and Photonics: Essential Technologies for Our Nation” report published by the National Research Council of the National Academies, optics and photonics technologies have tremendous potential to enable entirely new innovations that create high-volume, high-value solutions in the areas of manufacturing, communications, information, medicine, defense, security, and energy.

“The ChromaID Scanner and SDK will give engineers an opportunity to explore firsthand the many potential applications of ChromaID in their industry. ChromaID takes substance identification out of the lab and into daily life, spawning a wave of new consumer and industrial applications,” said Erickson. “Putting this disruptive technology in the hands of the brightest people at the world’s most innovative companies presents a tremendous opportunity for the creation of applications across a variety of industries. Already, our beta users are surprising us with exciting applications.”

The ChromaID Scanner shines Visualant’s patented structured light – light at specific ultra-violet, visible, and near-infrared wavelengths – on substances and materials, then records the reflection, resulting in a unique identifier of the sample called ChromaID. The included ChromaID Lab software allows users to calibrate each scan, and to record, review, and interpret the results according to their needs.

The portability and capability of the ChromaID SDK will support developers in creating new products featuring hand-held, real-time identification of virtually any substance or material. Potential applications include pollution control, drug detection, identity verification, counterfeit detection, medical diagnosis, and much more.

About Visualant, Inc.

Visualant™ is a public company whose shares trade under the stock symbol “VSUL.” The Visualant Spectral Pattern Matching™ (SPM) technology directs structured light onto a substance or material, through a liquid or gas, or off a surface, to capture a unique ChromaID™. A ChromaID can be used to identify, detect, or diagnosis markers invisible to the human eye. ChromaID scanner modules can be integrated into a variety of mobile or fixed-mount form factors. The patented, award-winning technology is disruptive, making it possible to effectively conduct analyses in the field that could only previously be performed by large and expensive lab-based tests.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.